S. Mpofu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. Mpofu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
L. S. Teh
1 shared publicationP. J. Smith
1 shared publicationP. N. Hawkins
1 shared publicationR J Moots
1 shared publicationR. J. Moots
1 shared publication
Latest Publications
- Open Access
- 1 April 2003
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (4) , 376
A case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies
A 48 year old man presented to the orthopaedic clinic with left knee and foot pain and an associated mild weakness on the left side. Examination confirmed patellofemoral crepitus, and spastic paraparesis. A diagnosis of MS was made, supported by oligoclonal bands in cerebral spinal fluid, delayed visual evoked responses, and magnetic resonance imaging studies which showed high intensity areas in the brainstem tegmentum and periventricular white matter. His main deficit was spasticity of the legs and intermittent pains in hands and feet. He was mobile with crutches. Baclofen or dantrolene in therapeutic doses did not improve his spasticity.
- 1 April 2003
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (4) , 376
Open AccessA case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies
A 48 year old man presented to the orthopaedic clinic with left knee and foot pain and an associated mild weakness on the left side. Examination confirmed patellofemoral crepitus, and spastic paraparesis. A diagnosis of MS was made, supported by oligoclonal bands in cerebral spinal fluid, delayed visual evoked responses, and magnetic resonance imaging studies which showed high intensity areas in the brainstem tegmentum and periventricular white matter. His main deficit was spasticity of the legs and intermittent pains in hands and feet. He was mobile with crutches. Baclofen or dantrolene in therapeutic doses did not improve his spasticity.
- Open Access
- 1 February 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (2) , 362-366
Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy
Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.
- 1 February 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (2) , 362-366
Open AccessCytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy
Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.